共 3 条
What does the future hold for cell-based tolerogenic therapy?
被引:111
作者:
Bluestone, Jeffrey A.
Thomson, Angus W.
Shevach, Ethan M.
Weiner, Howard L.
机构:
[1] Immune Tolerance Network, Diabetes Center, University of California San Francisco
[2] Department of Immunology, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA
[3] Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, NIH
[4] Robert L. Kroc Professor of Neurology, Harvard Medical School
[5] Center for Neurologic Diseases, Brigham and Women's Hospital, Boston
基金:
美国国家卫生研究院;
关键词:
D O I:
10.1038/nri2137
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Evidence from animal models has shown that the transfer of regulatory T cells or tolerogenic dendritic cells can prevent or cure transplant rejection or re-establish self-tolerance in autoimmune disease. The potential of these tolerogenic cells for the treatment of T-cell-mediated diseases in humans has gained momentum in recent years. Here, Nature Reviews Immunology asks four leading researchers to provide their view on the future of cell-based tolerogenic therapy and to highlight some important issues that must be considered before this form of immunotherapy can become a reality.
引用
收藏
页码:650 / 654
页数:6
相关论文